working

Sign up for free to access

Get access to the latest equity research in real-time from 12 commissioned providers.

Get access to the latest equity research in real-time from 12 commissioned providers.


Get Started
Already a member? Log in here

More Content

More Content

Long COVID is estimated to lead to about $2b-$6.5b of related costs/year for the ~44 to 48m people suffering in the U.S.

Companies: Aethlon Medical Inc (AEMD:NYSE)Aethlon Medical, Inc. (AEMD:NAS)

AEMD: Data From In Vitro Study Supports Advancing Planned Oncology Clinical Trial

Companies: Aethlon Medical Inc (AEMD:NYSE)Aethlon Medical, Inc. (AEMD:NAS)

The company expects to conduct a capital raise that, along with the expected (and recent) exercise of outstanding warrants, could extend its cash runway significantly.

Companies: Aethlon Medical Inc (AEMD:NYSE)Aethlon Medical, Inc. (AEMD:NAS)

Ethics Committee Approval for Safety, Feasibility, Dose-Finding Trial Important Step in Advancing the Hemopurifier

Companies: Aethlon Medical Inc (AEMD:NYSE)Aethlon Medical, Inc. (AEMD:NAS)

AEMD recently made some headcount reductions and other cost reductions and stands to benefit from the up to 43.5% cash tax rebate on clinical trial-related R&D costs in Australia.

Companies: Aethlon Medical Inc (AEMD:NYSE)Aethlon Medical, Inc. (AEMD:NAS)

© Research Tree 2025

  • Apple Store
  • Play Store

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top